NZ601055A - Radioimmunoconjugates and uses thereof - Google Patents

Radioimmunoconjugates and uses thereof

Info

Publication number
NZ601055A
NZ601055A NZ601055A NZ60105511A NZ601055A NZ 601055 A NZ601055 A NZ 601055A NZ 601055 A NZ601055 A NZ 601055A NZ 60105511 A NZ60105511 A NZ 60105511A NZ 601055 A NZ601055 A NZ 601055A
Authority
NZ
New Zealand
Prior art keywords
radioimmunoconjugates
radioimmunoconjugate
disclosed
group
monoclonal antibody
Prior art date
Application number
NZ601055A
Other languages
English (en)
Inventor
Roy H Larsen
Oyvind S Bruland
Jostein Dahle
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of NZ601055A publication Critical patent/NZ601055A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ601055A 2010-01-29 2011-01-28 Radioimmunoconjugates and uses thereof NZ601055A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
NZ601055A true NZ601055A (en) 2013-12-20

Family

ID=44319900

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601055A NZ601055A (en) 2010-01-29 2011-01-28 Radioimmunoconjugates and uses thereof

Country Status (25)

Country Link
US (2) US8628749B2 (enExample)
EP (2) EP2705857B1 (enExample)
JP (2) JP5646652B2 (enExample)
KR (2) KR101893720B1 (enExample)
CN (2) CN104338154B (enExample)
AU (1) AU2011209441B2 (enExample)
BR (1) BR112012018843B8 (enExample)
CA (1) CA2786655C (enExample)
DK (2) DK2705857T3 (enExample)
ES (2) ES2469140T3 (enExample)
HR (1) HRP20140538T1 (enExample)
IL (2) IL221091A (enExample)
MX (2) MX342539B (enExample)
NO (1) NO331080B1 (enExample)
NZ (1) NZ601055A (enExample)
PH (2) PH12012501516A1 (enExample)
PL (1) PL2528627T3 (enExample)
PT (1) PT2528627E (enExample)
RS (1) RS53346B (enExample)
RU (2) RU2560587C9 (enExample)
SG (1) SG182685A1 (enExample)
SI (1) SI2528627T1 (enExample)
UA (1) UA108631C2 (enExample)
WO (1) WO2011092295A2 (enExample)
ZA (1) ZA201205007B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203372A1 (en) * 2011-12-13 2015-10-30 Nordic Nanovector Asa Chimeric therapeutic anti - cd37 antibodie hh1
US20150093397A1 (en) * 2012-03-30 2015-04-02 Immunogen, Inc. Methods for Increasing Efficacy of CD37-Based Therapy
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
EP3332813B1 (en) * 2013-06-07 2019-05-29 Nordic Nanovector ASA Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
BR112017020689A2 (en) * 2015-04-07 2018-06-26 Memorial Sloan-Kettering Cancer Center nanoparticulate immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
JP2019529433A (ja) * 2016-09-16 2019-10-17 ノルディック ナノベクター アルメン アクスイェ セルスカプ リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN117241832A (zh) * 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
RU2005122033A (ru) * 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1587550B1 (en) * 2003-01-31 2011-07-27 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
HK1179157A1 (en) 2013-09-27
PH12017501038B1 (en) 2019-02-22
PL2528627T3 (pl) 2014-08-29
IL221091A0 (en) 2012-09-24
US9358309B2 (en) 2016-06-07
JP5855209B2 (ja) 2016-02-09
EP2705857A2 (en) 2014-03-12
PT2528627E (pt) 2014-06-12
HRP20140538T1 (hr) 2014-07-18
US20120301396A1 (en) 2012-11-29
RU2560587C9 (ru) 2015-11-27
KR101758409B1 (ko) 2017-07-14
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
CN102762230A (zh) 2012-10-31
PH12012501516A1 (en) 2024-04-03
EP2705857B1 (en) 2016-06-22
BR112012018843B8 (pt) 2020-12-22
JP2013518086A (ja) 2013-05-20
CA2786655A1 (en) 2011-08-04
BR112012018843B1 (pt) 2020-09-24
EP2528627B1 (en) 2014-03-19
KR101893720B1 (ko) 2018-08-30
NO331080B1 (no) 2011-09-26
SI2528627T1 (sl) 2014-08-29
KR20130028051A (ko) 2013-03-18
RU2560587C2 (ru) 2015-08-20
US20140147384A1 (en) 2014-05-29
EP2528627A2 (en) 2012-12-05
JP2015057415A (ja) 2015-03-26
EP2705857A3 (en) 2014-07-30
BR112012018843A2 (pt) 2017-10-17
CA2786655C (en) 2016-12-13
ES2469140T3 (es) 2014-06-17
CN104338154A (zh) 2015-02-11
IL237507A0 (en) 2015-04-30
AU2011209441B2 (en) 2016-03-03
CN102762230B (zh) 2014-08-13
PH12017501038A1 (en) 2017-12-11
JP5646652B2 (ja) 2014-12-24
BR112012018843A8 (pt) 2017-12-19
IL221091A (en) 2015-03-31
CN104338154B (zh) 2017-09-22
RS53346B (sr) 2014-10-31
US8628749B2 (en) 2014-01-14
AU2011209441A1 (en) 2012-07-19
ES2592402T3 (es) 2016-11-30
MX2012008695A (es) 2012-11-23
WO2011092295A3 (en) 2011-11-24
DK2528627T3 (da) 2014-05-12
HK1195736A1 (en) 2014-11-21
DK2705857T3 (en) 2016-08-29
NO20100143A1 (no) 2011-08-01
MX342539B (es) 2016-10-04
RU2012135430A (ru) 2014-03-10
WO2011092295A2 (en) 2011-08-04
ZA201205007B (en) 2013-09-25
UA108631C2 (xx) 2015-05-25
KR20170084349A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
NZ601055A (en) Radioimmunoconjugates and uses thereof
NZ602294A (en) Monoclonal antibodies against c-met
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
UA101487C2 (en) Humanized b-ly1 antibody formulation
PH12014501338A1 (en) Chimeric therapeutic anti-cd37 antibodie hh1
GEP20237497B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
NZ602176A (en) Cd37-binding molecules and immunoconjugates thereof
NZ597251A (en) Antibodies and immunoconjugates and uses therefor
IL238667A0 (en) Monoclonal antibodies against cld18 for cancer treatment
TN2014000107A1 (en) Anti-aplhabetatcr antibody
NZ602040A (en) Anti-lrp6 antibodies
WO2009083009A3 (en) Monoclonal antibodies against cd32b
EA201000274A1 (ru) Антитела к cd37
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
NZ604007A (en) Monoclonal antibodies against her2 epitope
SG178886A1 (en) Humanized anti-cdcp1 antibodies
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
MX2009010412A (es) Composiciones para formacion de imagen objetivo y terapia.
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
MX2022016300A (es) Anticuerpo anti-trop2.
TN2009000233A1 (en) Radiolabelling via fluorination of aziridines
NZ737925A (en) Monoclonal antibodies against c-met
UA110698C2 (uk) Антитіло проти cd37 та його імунокон'югати

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2016 BY DENNEMEYER + CO

Effective date: 20141219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220117

LAPS Patent lapsed